PetriKey

Antimicrobial

Neuraminidase inhibitors

Block influenza virion release

noor-uh-MIN-ih-days in-HIB-ih-terz

antiviralinfluenzaneuraminidasemechanismsialic-acid

High-yield clue

Neuraminidase inhibitors stop cleavage of sialic acid so new virions stay stuck to the host cell and cannot spread.

Overview

An antiviral class (oseltamivir, zanamivir, peramivir) whose mechanism concept is blocking the influenza surface enzyme neuraminidase, studied to connect viral enzyme structure to virion release.

Classification

  • Antiviral
  • Sialic-acid analog
  • Influenza A and B activity
  • Neuraminidase (N-spike) target

Lab & identification clues

  • Neuraminidase enzyme cleaves host-cell sialic acid vocabulary
  • Influenza has both hemagglutinin (H) and neuraminidase (N) spikes
  • Resistance vocabulary tied to neuraminidase active-site mutations

Associations

  • Influenza virus release mechanism concept
  • Seasonal influenza study framing
  • H and N surface glycoprotein antigen vocabulary

Commonly confused with

  • M2 ion-channel blockers (amantadine)
  • Baloxavir (endonuclease inhibitor)

Your notes

Original mechanism summary for microbiology study. Sources checked: CDC antimicrobial-resistance guidance, NCBI Bookshelf Medical Microbiology, and standard coursework frameworks; reviewed 2026-06. Covers class, mechanism, and resistance vocabulary only; no prescribing, dosing, or patient-specific treatment guidance.

CDC: CDC antimicrobial resistance overview and threat reportssourceWHO: WHO bacterial priority pathogens list 2024sourceNCBI Bookshelf: Medical Microbiology antimicrobial mechanism foundationssource